Drug intelligence / Profile preview

cisplatin + duoxitasai

Development stage: Preclinical
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules
Administration: Intravenous

Overview

Cisplatin + duoxitasai is a chemotherapy combination used in cancer treatment. Cisplatin is a platinum-based alkylating agent that works by cross-linking DNA strands, preventing cell division and causing cell death. Duoxitasai is manufactured by Jiangsu Hengrui Medical Limited Company in China. This combination has been used in the treatment of various cancers, including desmoplastic small round cell tumors.

Other names: DP regimen

Targets

DNA

Beyond the preview

Go deeper on cisplatin + duoxitasai.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cisplatin + duoxitasai.

Explore the full profile